CV vs DNTH: fair value comparison
CapsoVision, Inc. and Dianthus Therapeutics, Inc. · Updated 2026-10-19
CV has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. DNTH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CV currently ranks higher by quality score.
| CV | DNTH | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $6.53 | $72.09 |
| 12-month range | $4.59–$14.42 | $32.92–$115.96 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #184 of 301 Healthcare | #185 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Mixed |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: CV fair value analysis · DNTH fair value analysis